The OPTION trial evaluated IV tenecteplase (0.25 mg/kg) in CT perfusion–selected non-LVO ischemic stroke patients treated 4.5–24 hours after last-known-well. Tenecteplase improved excellent 90-day outcomes (mRS 0–1) but increased symptomatic intracranial hemorrhage, with the benefit–harm balance sensitive to outcome and ...
The HAT and SEDAN scores help estimate symptomatic intracranial hemorrhage risk after stroke thrombolysis. This comparison reviews what each tool measures, when to use them, and the key limitations clinicians should know.
Need a quick, reliable coma scale in real ED chaos? SMS simplifies assessment, while FOUR adds brainstem and respiratory data when it matters most.
The cornerstone of acute ischemic stroke (AIS) management involves timely reperfusion of the ischemic brain tissue. Intravenous thrombolysis with alteplase has been the standard of care for AIS within 4.5 hours of symptom onset, based on pivotal trials such as ...
Ketamine was first introduced for human use in 1965 and has been widely utilized as a general anesthetic with an excellent safety profile (Mion 2017, Dorandeu 2013). Ketamine works on several receptors, resulting in various actions such as anesthesia, analgesia, ...
© 2022 REBEL EM. All rights reserved. | Disclaimer | Website by Innov8 Place.
